Related Experiment Videos
[Clinical experience of cefotaxime (author's transl)]
Abstract:
Seventeen septicaemia, 18 urinary tract infections, 13 acute bacterial pulmonary infections and 7 infections at various other site were treated with cefotaxime, and, in 48 cases, with cefotaxime alone. The pathogenic organisms were mainly enterobacteria: 19 E. coli, 10 Klebsiella, 8 Proteus, 2 Serratia, 1 Enterobacter, almost all of them having a MIC less than or equal to 1 mcg/ml. The route of administration used was the i.m. route in 33 cases and the i.v. route in 18 cases, both routes having been used in 4 patients. The mean dosage was 45 mg/kg/day. A cure was obtained in 49 cases were clinical and bacteriological results were interpretable (85,7% of cases). The cure rate was 80% in septicaemia, 88,2% in urinary infections and 91,6% in pulmonary infections. In 19 infections due to beta-lactamase producing strains of Gram-negative bacteria, the percentage of cure was 68,4%. The systemic and local tolerance was excellent. Cefotaxime is a very well tolerated and very effective antibiotic, even in prolonged treatment and even in monotherapy, at a mean dosage of 50 mg/kg/day.
Insights
Cefotaxime effectively treated various bacterial infections, including septicaemia, urinary tract, and pulmonary infections, with an 85.7% cure rate. This antibiotic demonstrated excellent tolerance, even in monotherapy for Gram-negative bacterial infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Bacteriology
Context:
- Bacterial infections pose a significant global health challenge.
- Enterobacteriaceae are common causative agents of various infections.
- Antibiotic resistance, particularly beta-lactamase production, complicates treatment.
Purpose:
- To evaluate the efficacy and safety of cefotaxime in treating diverse bacterial infections.
- To assess cefotaxime's effectiveness against Gram-negative bacteria, including beta-lactamase producers.
- To determine optimal dosage and administration routes for cefotaxime therapy.
Summary:
- A study treated 57 patients with cefotaxime for infections like septicaemia, UTIs, and pulmonary infections, achieving an 85.7% cure rate.
- Pathogens included E. coli, Klebsiella, and Proteus, with most susceptible to cefotaxime (MIC ≤ 1 mcg/ml).
- Cure rates varied by infection type (80-91.6%), with 68.4% success in beta-lactamase producing infections. Mean dosage was 45-50 mg/kg/day.
Impact:
- Cefotaxime is a well-tolerated and highly effective antibiotic for bacterial infections.
- Demonstrates utility in monotherapy and prolonged treatment regimens.
- Offers a viable option against infections caused by Gram-negative bacteria.